Want to see GANX full AI Analyst Report?
Gain Therapeutics (GANX) Income Statement
Gain Therapeutics Income Statement
Last quarter (Q2 2026), Gain Therapeutics's total revenue was $0.00. In Q2, Gain Therapeutics's net income was $-4.68M. See Gain Therapeutics’s key income statements, including revenue, expenses, profit, and income.
| Income Statement | Dec 25 | Dec 24 | Dec 23 | Dec 22 | Dec 21 |
|---|---|---|---|---|---|
| $ 0.00 | $ 0.00 | $ 55.18K | $ 140.11K | $ 164.99K | |
| $ 0.00 | $ 0.00 | $ 55.18K | $ 140.11K | $ 164.99K | |
| $ 18.71M | $ 20.35M | $ 22.31M | $ 17.92M | $ 13.99M | |
| Depreciation and Amortization | $ 94.05K | $ 84.07K | $ 83.58K | $ 64.17K | $ 15.48K |
| $ -19.21M | $ -19.79M | $ -22.10M | $ -17.43M | $ -13.87M | |
| $ -18.71M | $ -20.35M | $ -22.25M | $ -17.78M | $ -13.83M | |
| $ -589.28K | $ 476.22K | $ 64.89K | $ 279.28K | $ -60.42K | |
| $ -19.30M | $ -19.87M | $ -22.19M | $ -17.50M | $ -13.89M | |
| $ -20.16M | $ -20.41M | $ -22.27M | $ -17.59M | $ -13.89M | |
| Per Share Metrics | |||||
| Basic EPS | $ -0.61 | $ -0.89 | $ -1.71 | $ -1.48 | $ -1.37 |
| Diluted EPS | $ -0.61 | $ -0.89 | $ -1.71 | $ -1.48 | $ -1.37 |
| Weighted Average Shares Outstanding | 32.97M | 22.88M | 13.01M | 11.88M | 10.17M |
| Weighted Average Shares Outstanding (Diluted) | 32.97M | 22.88M | 13.01M | 11.88M | 10.17M |
Currency in USD
